XENON PHARMACEUTICALS INC. (XENE) FY2026 Q2 Statement of Cash Flows

Statement of Cash Flows

2026-04-01 to 2026-06-30

Swipe to see the full flow
XENON PHARMACEUTICALS INC. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Proceeds from exercise of stock options → financing reconciliation: $26,000.00financing reconciliation → Net cash from financing activities: $26,000.00Proceeds from marketable securities → investing reconciliation: $159,419,000.00investing reconciliation → Purchases of marketable securities: $490,382,000.00investing reconciliation → Purchases of property, plant and equipment: $275,000.00Net cash used in operating activities → operating reconciliation: $95,390,000.00Stock-based compensation expense → operating reconciliation: $16,732,000.00Accounts payable and accrued liabilities → operating reconciliation: $5,716,000.00Depreciation of property plant and equipment → operating reconciliation: $558,000.00Non-cash operating lease expense → operating reconciliation: $325,000.00Other liabilities → operating reconciliation: $41,000.00operating reconciliation → Net loss: $110,736,000.00operating reconciliation → Prepaid expenses and other current assets: $2,501,000.00operating reconciliation → Interest receivable and accretion of discounts on marketable securities: $2,031,000.00operating reconciliation → Deferred income tax recovery: $1,944,000.00operating reconciliation → Other receivables: $467,000.00operating reconciliation → Unrealized foreign exchange gain: $458,000.00operating reconciliation → Operating lease liability: $358,000.00operating reconciliation → Realized (gain) loss on marketable securities: $267,000.00Net cash used in investing activities → investing reconciliation: $331,238,000.00Exchange-rate effect → Cash sources and uses: $262,000.00Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations → Cash sources and uses: $545,867,000.00Net cash from financing activities → Cash sources and uses: $26,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $119,527,000.00Cash sources and uses → Net cash used in investing activities: $331,238,000.00Cash sources and uses → Net cash used in operating activities: $95,390,000.00Interest receivable and accretion of discounts on marketable securities: -$2,031,000.00Interest receivable & accretion−$2.03 MOther liabilities: $41,000.00Other operating liabilities+$41.00 KNon-cash operating lease expense: $325,000.00Operating lease amortization+$325.00 KNet loss: -$110,736,000.00Net loss−$110.74 MDepreciation of property plant and equipment: $558,000.00Depreciation & amortization+$558.00 KDeferred income tax recovery: -$1,944,000.00Deferred income taxes−$1.94 MStock-based compensation expense: $16,732,000.00Stock-based compensation+$16.73 MRealized (gain) loss on marketable securities: -$267,000.00Realized securities gain & loss−$267.00 KUnrealized foreign exchange gain: -$458,000.00Unrealized FX gain & loss−$458.00 KOther receivables: -$467,000.00Other receivables−$467.00 KPrepaid expenses and other current assets: -$2,501,000.00Prepaid & other assets−$2.50 MOperating lease liability: -$358,000.00Operating lease liabilities−$358.00 KAccounts payable and accrued liabilities: $5,716,000.00Payables & accrued liabilities+$5.72 MNet cash used in operating activities: -$95,390,000.00. Cash required to fund net payments.Operating cash−$95.39 Moperating reconciliation: $118,762,000.00Proceeds from offerings, net: $0.00Proceeds from exercise of stock options: $26,000.00Stock option exercises+$26.00 KNet cash from financing activities: $26,000.00Financing cash+$26.00 Kfinancing reconciliation: $26,000.00Purchases of property, plant and equipment: -$275,000.00PP&E purchases−$275.00 KPurchases of marketable securities: -$490,382,000.00Marketable securities purchases−$490.38 MProceeds from marketable securities: $159,419,000.00Marketable securities proceeds+$159.42 MNet cash used in investing activities: -$331,238,000.00. Cash required to fund net payments.Investing cash−$331.24 Minvesting reconciliation: $490,657,000.00Cash sources and uses: $546,155,000.00Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $545,867,000.00Beginning cash$545.87 MEnding cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $119,527,000.00Ending cash$119.53 MExchange-rate effect: $262,000.00FX effect+$262.00 KCASH RECONCILIATIONFinancingflowsInvestingflowsOperatingflowsNet loss −$110.74M + net operating adjustments $15.35M = operating cash −$95.39MFree cash flow−$95.67 MOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change−$426.34 MEnding cash − beginning cash
Chart details

XENON PHARMACEUTICALS INC. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026

Cash flows for Apr 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations. Beginning cash: Mar 31, 2026. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Mar 31, 2026
545,867,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
Operating activities
negative 95,390,000 US dollars. Net cash used.
Interest receivable and accretion of discounts on marketable securities
negative 2,031,000 US dollars
Other liabilities
41,000 US dollars
Non-cash operating lease expense
325,000 US dollars
Net loss
negative 110,736,000 US dollars
Depreciation of property plant and equipment
558,000 US dollars
Deferred income tax recovery
negative 1,944,000 US dollars
Stock-based compensation expense
16,732,000 US dollars
Realized (gain) loss on marketable securities
negative 267,000 US dollars
Unrealized foreign exchange gain
negative 458,000 US dollars
Other receivables
negative 467,000 US dollars
Prepaid expenses and other current assets
negative 2,501,000 US dollars
Operating lease liability
negative 358,000 US dollars
Accounts payable and accrued liabilities
5,716,000 US dollars
Investing activities
negative 331,238,000 US dollars. Net cash used.
Purchases of property, plant and equipment
negative 275,000 US dollars
Purchases of marketable securities
negative 490,382,000 US dollars
Proceeds from marketable securities
159,419,000 US dollars
Financing activities
26,000 US dollars. Net cash provided.
Proceeds from offerings, net
0 US dollars
Proceeds from exercise of stock options
26,000 US dollars
Operating adjustment reconciliation
118,762,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
26,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
490,657,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
262,000 US dollars
Ending cash on Jun 30, 2026
119,527,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
Cash sources and uses
546,155,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 426,340,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
negative 95,390,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
275,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
negative 95,665,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$110.74M + net operating adjustments $15.35M = operating cash −$95.39M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: negative 95,390,000 US dollars minus 275,000 US dollars equals negative 95,665,000 US dollars.
XENON PHARMACEUTICALS INC. (XENE) FY2026 Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!